Showing results (301-310 of 369) with videos related to

Sort By:
Pageof 37
Molecular Cancer Therapeutics|August 10, 2004
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancerDaniel E H Afar, Vinay Bhaskar, Eric Ibsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working GroupHoward I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2022
The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate CancerGoutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or EnzalutamideLandon C Brown, Susan Halabi, Joseph D Schonhoft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
Cancer Cell|June 29, 2010
Integrative genomic profiling of human prostate cancerBarry S Taylor, Nikolaus Schultz, Haley Hieronymus, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 16, 2010
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and developmentTina Bianco-Miotto, Karen Chiam, Grant Buchanan, et al.
Science Translational Medicine|December 2, 2016
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axisDaniel L J Thorek, Philip A Watson, Sang-Gyu Lee, et al.
Pageof 37